gyki 52466 has been researched along with Cerebral Infarction in 2 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchan, AM | 2 |
| Lesiuk, H | 1 |
| Barnes, KA | 1 |
| Li, H | 1 |
| Huang, ZG | 2 |
| Smith, KE | 2 |
| Xue, D | 2 |
| Barnes, K | 1 |
| Lesiuk, HJ | 1 |
2 other studies available for gyki 52466 and Cerebral Infarction
| Article | Year |
|---|---|
AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1993 |
Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1994 |